Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Honey bee hymenoptera venom** is a sterile lyophilized biologic allergenic extract derived from *Apis mellifera* venom and used for both diagnosis of honey bee venom hypersensitivity and venom immunotherapy to reduce the risk of systemic allergic reactions after future bee stings. It is supplied as a freeze-dried powder for reconstitution, administered primarily by subcutaneous injection for immunotherapy and by percutaneous or intradermal skin testing for diagnosis. Its therapeutic effect is mediated not by blockade of a single molecular receptor, but by controlled exposure to whole bee venom allergens that modulates the patient's venom-specific immune response, reducing pathologic IgE-mediated reactivity and promoting clinical desensitization. The product has been marketed in the United States, including under the Venomil brand, and is manufactured by Jubilant HollisterStier.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on honey bee hymenoptera venom.